MedTrace Logo

Impact of Ascorbic Acid in the Prevention of Vancomycin Induced Nephrotoxicty

NCT03921099 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-01-10

No results posted yet for this study

Summary

A Randomized controlled trial aiming to investigate whether ascorbic acid has a role in preventing vancomycin induced nephrotoxicity or not in critically ill patients.

Conditions

Interventions

DRUG

Ascorbic Acid

ascorbic acid is an antioxidant that is expected to prevent nephrotoxicty induced by Vancomycin.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Nagwa A Sabry, PhD · Ain Shams University

  • Sara M Shaheen, PhD · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-17
Primary Completion
2020-07-31
Completion
2020-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03921099 on ClinicalTrials.gov